Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Cemiplimab + Chemotherapy + Cetuximab in Resectable HNSCC
NCT04722523Phase 1Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2021
- Primary completion
- Jun 2027
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of cemiplimab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Incidence of toxicities graded according to NCI CTCAE at 1 year. Started Jan 2021; status: recruiting.
02
Drugs
cemiplimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04722523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04722523.